SCHEMBL5455402

SCHEMBL5455402

Cc1cccc(Cc2ccc(S(=O)(=O)c3cc4c(cc3N(C)C)CCN(C)CC4)cc2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.38
USP2 O75604 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 2/20 0.38
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HTR6 P50406 5/20 0.35
RORC P51449 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
DRD2 P14416 1/20 0.34
CYP2C19 P33261 1/20 0.34
DRD3 P35462 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14411990 0.90 HTR6 (0.43) HRH3USP2SMN1; SMN2HTR2AHTR2C
SCHEMBL5453002 0.90 USP2 (0.42) USP2SMN1; SMN2HTR2AHTR2CKMT2A
SCHEMBL5458151 0.89 LTA4H (0.43) USP2SMN1; SMN2HTR2AHTR2CMEN1
SCHEMBL5466786 0.89 SIGMAR1 (0.42) USP2SMN1; SMN2HTR2AHTR2CKMT2A
SCHEMBL5448126 0.87 LTA4H (0.47) HRH3USP2MEN1KMT2APOLB
SCHEMBL5451428 0.86 GALR3 (0.42) USP2SMN1; SMN2HTR2AHTR2CMEN1
SCHEMBL5450675 0.86 KCNH2 (0.39) HRH3USP2SMN1; SMN2HTR2AHTR2C
SCHEMBL5452773 0.86 USP2 (0.42) USP2SMN1; SMN2HTR2AHTR2CHTR6
SCHEMBL5452896 0.85 HTR2C (0.42) USP2SMN1; SMN2HTR2AHTR2CHTR6
SCHEMBL5462456 0.85 USP2 (0.41) HRH3USP2SMN1; SMN2HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US claimed
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US disclosed
EP-1687005-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2006-08-09 EP disclosed
WO-2005051398-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents HTR4, DRD4, SLC6A3 HRH3 72/4885USP2 4595/4885SMN1; SMN2 2075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.